Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer

     Trovagene Appoints Mark Erlander, Ph.D. as Chief Scientific Officer

PR Newswire

SAN DIEGO, March 4, 2013

SAN DIEGO, March 4, 2013 /PRNewswire/ --Trovagene, Inc. (NASDAQ:TROV), a
developer of transrenal molecular diagnostics, today announced that Mark
Erlander, Ph.D., has joined the company as chief scientific officer. Dr.
Erlander has more than 18 years of experience directing research teams with a
strong focus in oncology-based molecular diagnostics. He has developed
multiple novel molecular diagnostic assays from biomarker discovery to test
commercialization, notably CancerTYPE ID® and Breast Cancer Index^SM. Dr.
Erlander has overseen a significant portfolio of retrospective and prospective
clinical studies to establish both clinical validity and utility of these


As chief scientific officer for Trovagene, Dr. Erlander will direct the
clinical development program for the company's portfolio of transrenal and
urine-based molecular diagnostic assays. Clinical studies will initially focus
on Trovagene's oncogene mutation tests currently in development. Dr. Erlander
will also oversee the ongoing clinical program for Trovagene's human papilloma
virus (HPV) carrier screening assay.

"As we move toward commercial availability for our urine-based HPV carrier
screening and oncogene mutation tests, we are significantly expanding our
clinical development capabilities. Mark's expertise will be invaluable in this
pursuit," said Antonius Schuh, Ph.D., chief executive officer of Trovagene.

"The promise of urine-based oncogene mutation detection and testing has the
potential to be transformative in cancer care," said Dr. Erlander. "The
ability to detect oncogene mutation signals in cell free DNA combined with the
significant advantage of using urine as a sample represents an intriguing
opportunity to improve patient monitoring."

Dr. Erlander previously served as chief scientific officer of bioTheranostics
(a bioMerieux company), a molecular oncology diagnostics laboratory based in
San Diego. Prior to bioTheranostics, Dr. Erlander was a research fellow at the
R.W. Johnson Pharmaceutical Research Institute (Johnson & Johnson). Earlier in
his career, he was a postdoctoral fellow in the Department of Molecular
Biology at The Scripps Research Institute, La Jolla.

Dr. Erlander holds a BS degree in Biochemistry from the University of
California, Davis; a MS degree in Biochemistry from Iowa State University; and
a Ph.D. in Neuroscience from the University of California, Los Angeles. He
holds 38 issued U.S. patents in the areas of diagnostics, therapeutics and
genomic technologies, and is an author of 73 scientific publications with 56
peer-reviewed original articles and 17 review/chapter publications.

CancerTYPE ID® and Breast Cancer Index^SM are registered marks of
bioTheranostics, a bioMerieux company.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented
technology for the detection of transrenal DNA and RNA, short nucleic acid
fragments, originating from normal and diseased cell death that cross the
kidney barrier and can be detected in urine. Trovagene is leveraging its
intellectual property in oncogene mutations via out-licensing and use of its
transrenal technologies to extend oncogene mutation detection using urine as a
sample. As a non-invasive and abundant sample, urine may overcome many of the
cost and collection challenges associated with biopsy, as well as the volume
limitations of blood.

Trovagene has a strong patent position as it relates to transrenal molecular
testing. It has U.S. and European patent applications and issued patents that
cover testing for HPV and other infectious diseases, cancer, transplantation,
prenatal and genetic testing. In addition, it owns worldwide rights to
nucleophosmin-1 (NPM1), an informative biomarker for acute myelogenous
leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be
associated with chemotherapy response in chronic lymphocytic leukemia (CLL)
patients, as well as other hematologic malignancies.

Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995. These
statements may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend," among others.
These forward-looking statements are based on Trovagene's current expectations
and actual results could differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not limited to,
substantial competition; our ability to continue as a going concern; our need
for additional financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payer reimbursement; limited sales
and marketing efforts and dependence upon third parties; and risks related to
failure to obtain FDA clearances or approvals and noncompliance with FDA
regulations. As with any medical diagnostic tests under development, there are
significant risks in the development, regulatory approval and
commercialization of new products. There are no guarantees that future
clinical trials discussed in this press release will be completed or
successful or that any product will receive regulatory approval for any
indication or prove to be commercially successful. Trovagene does not
undertake an obligation to update or revise any forward-looking statement.
Investors should read the risk factors set forth in Trovagene's Form 10-K for
the year ended December 31, 2011 and other periodic reports filed with the
Securities and Exchange Commission.


Trovagene, Inc.
Amy Caterina
Investor Relations
+1 (858) 952-7593

SOURCE Trovagene, Inc.

Press spacebar to pause and continue. Press esc to stop.